Elda Righi, MDMassachusetts General Hospital Blockade of the CXCL12 and VEGF axes in ovarian cancer One of the reasons ovarian cancer progresses with few evident symptoms may be the combination of ways in which the cancer escapes the patient’s immune system and organizes a vascular supply to serve its own needs. CXCL12 and VEGF are […]
Read More
Masafumi Toyoshima, MD, PhDFred Hutchinson Cancer Research Center Identification of Targeted Therapies for MYC-Amplified Ovarian Cancer By Functional Genomics The main goal of Dr. Toyoshima’s research is to investigate whether MYC synthetic lethal genes can be therapeutic targets for ovarian cancer in women whose MYC gene is amplified. Using a siRNA screening strategy this study […]
Read More
Young Min Chung, PhDStanford University Targeting Ovarian Cancer with Combination of Olaparib and Trifluoperazine Dr. Chung is developing innovative therapeutic strategies by combining a clinically used small-molecule drug called trifluoperazine (TFP) and a chemical compound named Olaparib, which is an inhibitor of an enzyme called PARP, to suppress advanced ovarian cancer and to overcome PARP […]
Read More
Michael Goldberg, PhDDana-Farber Cancer Institute2014 Kirwin-Hinton Family Scholar Unraveling the role of ATR in DNA repair and ovarian cancer therapy The majority of cancer therapies attempt to kill tumor cells using drugs that are often toxic. Many patients relapse because residual cells can establish new drug-resistant tumors. Unlike traditional therapies, the immune system can adapt […]
Read More
Remi Buisson, PhDMassachusetts General Hospital Unraveling the role of ATR in DNA repair and ovarian cancer therapy Proteins involved in the surveillance of genomic integrity, including BRCA1, BRCA2, and PALB2, help detect damage to DNA in cells and ensure that repairs are made when needed. Cells with mutations in BRCA1, BRCA2, and PALB2 have been […]
Read More
David Pepin, PhDMassachusetts General Hospital AAV9 gene therapy using a novel engineered MIS to treat ovarian cancer Ovarian cancer tumors are made up mostly of cells that respond well to chemotherapy, but a minority of stem-like cells survive treatment and ultimately lead to chemoresistant recurrence. However, this type of cancer stem cell is inhibited by […]
Read More
Erin George, MDUniversity of Pennsylvania2016 Skacel Family Scholar Targeting the ATR/CHK1 pathway in high grade serous ovarian cancer with ATR inhibitors New treatments are needed for recurrent ovarian cancer, a subset of which is more aggressive than the original cancer and has no effective treatment. Aggressive recurrent cancers rely on DNA repair pathways, involving proteins […]
Read More
Achuth Padmanabhan, PhDBaylor College of Medicine2019 Skacel Family Scholar PROTAC-mediated degradation of oncogenic gain-of-function p53 mutants: A personalized therapeutic strategy for ovarian cancer Ovarian cancer is the fifth leading cause for cancer-associated deaths among women in the US and is associated with frequent mutations in p53 gene. While some mutations result in the loss of […]
Read More
Erin George, MDUniversity of Pennsylvania2019 Lynda’s Fund Scholar Award Strategies to optimize drug tolerability without compromising efficacy Most women with ovarian cancer present with advanced stage disease. Large surgeries and toxic chemotherapies are the mainstay of treatment and, despite advances in medicine, most ovarian cancers return. Every tumor is unique in its biology, allowing for […]
Read More
Yang Yang-Hartwich, PhDYale University2015 Cookie Laughlin Bridge Funding Award Targeting p53-regulated Twist1 Degradation to Inhibit Ovarian Cancer Metastasis Metastasis is a hallmark of advanced high-grade serous ovarian carcinoma. Turning off the ability of ovarian cancer to spread or metastasize to other places in the body would provide better therapies and prevent recurrence. The objective of […]
Read More